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Background. An enhanced meningitis surveillance network was established across the meningitis belt of
sub-Saharan Africa in 2003 to rapidly collect, disseminate, and use district weekly data on meningitis incidence.
Following 10 years’ experience with enhanced surveillance that included the introduction of a group A meningococ-
cal conjugate vaccine, PsA-TT (MenAfriVac), in 2010, we analyzed the data on meningitis incidence and case fatality
from countries reporting to the network.
Methods. After de-duplication and reconciliation, data were extracted from the surveillance bulletins and the
central database held by the World Health Organization Inter-country Support Team in Burkina Faso for countries
reporting consistently from 2004 through 2013 (Benin, Burkina Faso, Chad, Democratic Republic of Congo, Ghana,
Côte d’Ivoire, Mali, Niger, Nigeria, Togo).
Results. The 10 study countries reported 341 562 suspected and conﬁrmed cases over the 10-year study period,
with a marked peak in 2009 due to a large epidemic of group A Neisseria meningitidis (NmA) meningitis. Case fa-
tality was lowest (5.9%) during this year. A mean of 71 and 67 districts annually crossed the alert and epidemic
thresholds, respectively. The incidence rate of NmA meningitis fell >10-fold, from 0.27 per 100 000 in 2004–2010
to 0.02 per 100 000 in 2011–2013 (P < .0001).
Conclusions. In addition to supporting timely outbreak response, the enhanced meningitis surveillance system
provides a global overview of the epidemiology of meningitis in the region, despite limitations in data quality and
completeness. This study conﬁrms a dramatic fall in NmA incidence after the introduction of PsA-TT.
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Countries in the African “meningitis belt,” an area in
sub-Saharan Africa that stretches from Senegal in the
west to Ethiopia in the east, are susceptible to intermit-
tent devastating outbreaks of meningococcal meningi-
tis, with attack rates as high as 1% of the population
during major epidemics [1]. Most epidemics have
been due to group A Neisseria meningitidis (NmA),
and some have been due to groups C, W, and X
(NmC, NmW, and NmX, respectively). In 2003, coun-
tries put in place an enhanced meningitis surveillance
network with support of the World Health Organization
(WHO) and the Meningitis Vaccine Project, a joint
WHO/PATH initiative [2]. Standard operating proce-
dures for surveillance implementation were developed
and disseminated to participating countries; in short,
data on suspected cases and deaths are recorded and
transmitted weekly from health centers to the district
medical ofﬁcer, including zero reporting, and onward
by radio, telephone, fax, or email to provincial and na-
tional levels [3]. When available, cerebrospinal ﬂuid
(CSF) specimens are sent to microbiology laboratories
for the identiﬁcation of the pathogen by rapid diagnostic
test, polymerase chain reaction (PCR), latex agglutina-
tion test, or culture. Each country reports to the WHO
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Inter-country Support Team (WHO/IST) for West Africa each
week in the meningitis season, and monthly the rest of the year.
An electronic application was developed by WHO for the
compilation and analysis of the data. The system was implement-
ed in 2005, with the database hosted inWHO/IST. Following ini-
tial variation in the format of data on cases and deaths provided
by week and district, WHO/IST worked with reporting countries
to standardize the format. Most participating countries are now
providing data on the number of cases and deaths by district and
week in an electronic format based on a standardized Microsoft
Excel format or Microsoft Access. All ﬁles are automatically ex-
tracted and compiled in one database. Automated analysis and
processing of the data are carried out using the open-source soft-
ware package R [4]. The automated output for the bulletin in-
cludes tables, charts, maps, calculation of districts in epidemic
and alert, with the addition of customized maps and an assess-
ment of the current situation by WHO/IST [5].
Initially, in 2003, 8 countries (Benin, Burkina Faso, Chad,
Ghana, Mali, Niger, Nigeria, and Togo) contributed to this en-
hanced surveillance network. Promoted by country capacity-
building visits from theWHO/IST to other meningitis belt coun-
tries, the number of reporting countries increased to 13 in 2004.
The phased introduction of the group A meningococcal conju-
gate vaccine (PsA-TT) by mass campaigns across the meningitis
belt since 2010 [6] further drove country participation in en-
hanced surveillance. By 2013, 19 countries (Benin, Burkina
Faso, Cameroon, Central African Republic, Chad, Democratic
Republic of Congo, Ethiopia, Ghana, Guinea, Côte d’Ivoire, Mali,
Mauritania, Niger, Nigeria, Senegal, South Sudan, Sudan, The
Gambia, and Togo) reported to this network.We describe the ep-
idemiology of meningitis in countries that reported to the men-
ingitis bulletins each year from 2004 to 2013, including the initial
impact of PsA-TT on meningitis incidence.
METHODS
Deﬁnitions
Suspected Meningitis
A case of suspected meningitis was deﬁned as any person with
sudden onset of fever (>38.5°C rectal or 38.0°C axillary) and 1
of the following signs: neck stiffness, ﬂaccid neck (infants), bulg-
ing fontanelle (infants), convulsion, or other meningeal signs [3].
Conﬁrmed Meningitis
A case of conﬁrmed meningitis was deﬁned as any person with
meningeal signs and isolation of a causal pathogen (N. meningiti-
dis, Streptococcus pneumoniae [Spn],Haemophilus inﬂuenzae type
b [Hib]) from the CSF by culture, PCR, or rapid diagnostic test [3].
Alert Threshold
The alert threshold was deﬁned as an attack rate of 5 suspected
cases per 100 000 inhabitants per week in a district or subdistrict
(in populations ≥30 000); or as 2 cases in 1 week, or a higher in-
cidence than in a nonepidemic year (in populations <30 000) [5].
Crossing this threshold triggers the reinforcement of surveillance.
Epidemic Threshold
The epidemic threshold was deﬁned as an attack rate of 15 sus-
pected cases per 100 000 inhabitants in 1 week in a district or
subdistrict, or 10 per 100 000 if considered at high risk of an ep-
idemic (in populations≥30 000); or as 5 cases in 1 week or a dou-
bling of incidence in a 3-week period (in populations <30 000)
[7]. Crossing this threshold triggers the launch of vaccination
campaigns when the predominance of N. meningitidis is con-
ﬁrmed and the use of a speciﬁc antibiotic treatment protocol.
Data Analysis
Countries were included in this study if they contributed data to
WHO/IST each year between 2004 and 2013 (Benin, Burkina
Faso, Chad, Democratic Republic of Congo, Ghana, Ivory
Coast, Mali, Niger, Nigeria, Togo). After de-duplication and rec-
onciliation of data between the bulletins and the database, data
were extracted and analyzed using Microsoft Excel 2010, version
10 (Microsoft Corporation). Data on numbers of cases and deaths
were taken from the database, and data on pathogens and num-
bers of districts in alert and epidemicwere taken from the bulletins
at week 52 of each year. Where the database was incomplete—
that is, all countries in 2004, Chad in 2005, and Nigeria in
2005 and 2006—all data were taken from the bulletins. Popula-
tion estimates for 2004 to 2013 obtained from the United Nations
Statistics Division [8] and the World Development Indicators
were used to calculate overall incidence rates.
RESULTS
A total of 341 562 suspected and conﬁrmed cases were reported
from the 10 countries, with considerable variation by country
and year (Table 1). The irregular cyclical nature of meningitis
epidemics is shown in Figures 1 and 2, with the largest number
of cases in 2009 (n = 86 714) corresponding to a major epidemic
in Nigeria and Niger, and the second-largest peak in 2007
(n = 45 195) due to an epidemic in Burkina Faso (Table 1).
Case fatality was highest in 2004 and 2005 (13.7%) and re-
mained close to 10% in subsequent years apart from 2009,
the year of highest incidence, when fatality fell to 5.9%. The
weekly number of meningitis cases by year (Figure 2) demon-
strates the main seasonal peaks in the ﬁrst 5 months of the year.
Over the 10 years, 657 of 1470 reporting districts (on average,
number of reporting districts varies widely over the years) in the
10 countries reached the alert threshold and 615 reached the ep-
idemic threshold in 1 or more years. This corresponds to, re-
spectively, an average across the 10-year span of 66 (range,
11–119) and 62 (range, 5–216) districts annually.
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From 2004 to 2013, 15 001 positive results from CSF samples
were reported, of which 40% were positive for NmA, 26% for
Spn, 18% for NmW, 8% for other types of N. meningitidis,
4% for Hib, and 3% for other pathogens. Niger and Burkina
Faso contributed the highest numbers of laboratory-conﬁrmed
cases (45% and 28% of all conﬁrmed cases, respectively). The
proportion of suspected cases with an organism isolated rose
from 3.9% in 2004–2010 to 6.9% in 2011–2013.
Table 2 and Figure 3 show the changing distribution of indi-
vidual pathogens from conﬁrmed cases of bacterial meningitis
over the study period. NmA was the main cause of meningitis
until the introduction of PsA-TT in 2010. NmW was detected
more frequently between 2010 and 2013, and an epidemic of
NmX was seen in Niger in 2006. Other types of N. meningitidis
(NmB, NmC, and NmY) were uncommon: between 2010 and
2013, only 1 NmB case was conﬁrmed in Côte d’Ivoire in 2011
and 2 NmB cases in Ghana in 2012. Spn remained an important
cause of meningitis throughout the study period. Cases due to
Hib were found more frequently in 2004–2005 than in subse-
quent years (11.1% of conﬁrmed cases in 2004–2005 vs 3.2% in
2006–2013; χ2 with Yates correction, 236.0; P > .0001).
Comparing the period before (2004–2010) with the period after
(2011–2013) the introduction of PsA-TT, the incidence rate of
NmA meningitis fell >10-fold, from 0.27 per 100 000 to 0.02
per 100 000 (P < .0001). The incidence of meningitis due to
NmW rose after 2010, but not that due to other N. meningitidis
serogroups. It should be noted that a marked increase in the inci-
dence of NmWmeningitis occurred in the 2010meningitis season
(Table 2), before the introduction of PsA-TT at the end of 2010.
DISCUSSION
The acceptability of the enhanced surveillance system in the
meningitis belt is shown by the continuing and increasing
Table 1. Suspected and Conﬁrmed Meningitis Cases in 10 Countries of the African Meningitis Belt, 2004–2013
Year Benin Burkina Faso Chad DRC Ghana Côte d’Ivoire Mali Niger Nigeria Togo Total
2004 377 6252 863 13 367 982 464 1480 4081 659 305 28 830
2005 303 3626 1015 9082 430 527 454 1404 657 333 17 831
2006 316 19 134 1430 6109 371 705 1039 4465 5731 578 39 878
2007 502 26 878 1452 8645 461 760 977 1097 2642 723 44 137
2008 414 10 401 1093 8406 281 1131 1538 3757 6835 428 34 284
2009 416 4723 1505 9150 201 289 335 13 449 56 128 350 86 546
2010 323 6732 3147 8160 1129 151 482 2908 4983 460 28 475
2011 269 3875 5960 5167 773 141 430 1189 1165 440 19 409
2012 1165 6957 3874 10 142 956 500 688 314 1206 408 26 210
2013 833 2917 371 9326 454 255 358 311 871 266 15 962
Total 4918 91 495 20 710 87 554 6038 4923 7781 32 975 80 877 4291 341 562
Abbreviation: DRC, Democratic Republic of Congo.
Figure 1. Incidence rate of suspected and conﬁrmed cases of meningitis in the African meningitis belt by year (solid line) and case fatality (dotted line),
2004–2013.
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participation of the countries in contributing to the weekly
meningitis bulletin and the central database at Ouagadougou.
The bulletins provide a valuable and timely demonstration of
the evolution of meningitis through the meningitis season,
both of pathogens responsible and of districts crossing the
alert and epidemic threshold [9]. This system gives a rapid
and important overview of the changing trends in incidence
and pathogen distribution and helps in planning response to
epidemics, for example, providing information on outbreaks
to assist the International Coordinating Group on Vaccine Pro-
vision for Epidemic Meningitis Control (ICG) in decisions on
vaccine stocks and release. Between 2004 and 2013, 81 country
vaccine requests, targeting 248 districts, were submitted to the
ICG and approved from the 10 countries mentioned in this
study, followed by reactive vaccination campaigns (Communica-
tion with ICG Secretariat Focal Point). Alongside the beneﬁts
from the regional overview, the enhanced surveillance system
has driven reinforcement of surveillance in the participating coun-
tries including training and strengthening laboratory capacity [9].
Not surprisingly, there are limitations to the data complete-
ness and quality. Variation in incidence between countries may
partly reﬂect different sensitivities and speciﬁcities of national
Figure 2. Number of suspected and conﬁrmed meningitis cases by week in the African meningitis belt of 2004 (red), 2005 (orange), 2006 (yellow), 2007
(light green), 2008 (green), 2009 (light blue), 2010 (blue), 2011 (purple), 2012 (pink), and 2013 (gray).
Table 2. Conﬁrmed Meningitis Cases and Organisms Isolated From Cerebrospinal Fluid in Countries of the African Meningitis Belt, 2004–
2013
Year
Total Confirmed
Cases NmA NmW NmCa NmXa
Other Nm or
Undetermined Serogroupa Total Nm Spn Hib Other
2004 1321 616 111 32 759 438 124
2005 694 180 33 53 266 267 100 61
2006 1978 921 37 581 31 1570 258 83 67
2007 1086 609 62 9 680 282 74 50
2008 1449 1048 7 65 1120 242 48 39
2009 2590 1994 90 47 2131 350 34 75
2010 1633 430 718 4 55 13 1220 341 46 26
2011 1750 111 508 5 154 6 784 876 53 37
2012 1728 49 955 4 138 30 1176 487 40 25
2013 774 4 213 10 15 47 289 417 32 36
2004–2013 15 001 5962 2734 23 362 912 9993 3958 634 416
Abbreviations: Hib, Haemophilus influenzae type b; Nm, Neisseria meningitidis; NmA, Neisseria meningitidis group A; NmC, Neisseria meningitidis group C; NmW,
Neisseria meningitidis group W; NmX, Neisseria meningitidis group X; Spn, Streptococcus pneumoniae.
a For 2004–2009, “Other Nm” includes NmC, NmX apart from 2006 data for Niger.
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surveillance systems, whereas variation between years within
countries is more likely to be a true reﬂection of the well-
known irregular ﬂuctuations in meningitis incidence across
the meningitis belt [1]. Of the 10 countries, Burkina Faso had
the highest numbers of reported cases and also the highest
mean annual incidence rate at 59 suspected cases per 100 000
population. A comparison of incidence rate by country was
not presented, mainly because in many countries only part of
the country is at high risk of meningitis, whereas surveillance
reporting covers the whole country. Laboratory conﬁrmation
capacity also differs by country. Thus, the pathogen distribution
presented largely reﬂects the results of Burkina Faso and Niger,
as together they have contributed to >70% of laboratory-
conﬁrmed cases. Variable completeness of reporting to the da-
tabase was observed especially at district level by year and by
country. Suspected cases are notiﬁed based on a deﬁnition
that may be interpreted differently in countries according to
local practice, and the percentage of conﬁrmed cases was low,
although increasing. Duplication of data entry for the same dis-
trict and week were seen particularly in 2 countries (Democratic
Republic of Congo and Ghana) where there was more uncer-
tainty about the quality of the surveillance system and where
population data were not always updated after changes in dis-
trict boundaries. Data quality would be improved by database
tools and electronic surveillance applications allowing capture
and analysis of data in an electronic format at the lowest level
possible for the respective country. Regular checks of data com-
pleteness and data quality, with regular feedback to the data-
providing facilities, are also needed.
It is interesting that case fatality was highest in the ﬁrst 2
years of this study, possibly due to subsequent improvements in
case management and/or to changes in pathogen distribution.
These 2 years saw the highest proportion of conﬁrmed cases
due to Hib, and an overall decline in reported Hib meningitis,
likely associated with the rollout of Hib vaccines into childhood
immunization schedules in all 10 countries between 2002
(Ghana) and 2012 (Nigeria). Such a decline is not observed
with pneumococcal meningitis; pneumococcal vaccination
was only introduced in 2011 in Benin and Mali, then in 2012
in Ghana, and in 2013 in Burkina Faso. The low case fatality
in 2009 may reﬂect the high proportion of cases due to NmA
or to the overall lower reported case fatality in the main coun-
tries affected that year (Nigeria and Niger; data not shown). In a
systematic review of bacterial meningitis among African chil-
dren, median case fatality for meningococcal meningitis was
relatively low at 4% (range, 3%–6%) vs 25% (range, 4%–41%)
for Hib [10]. Although fatality was highest for pneumococcal
meningitis at 35% (range, 9%–67%), it is encouraging that the
overall case fatality in this study did not rise after 2010 despite a
higher proportion of conﬁrmed cases due to Spn.
The weekly incidence data show the expected seasonal peak-
ing of meningitis in the ﬁrst 5 months of the year, although ep-
idemics may start in December before the main season, and a
small peak in incidence is noted in week 44 of 2005 (Figure 2).
Although the risk factors predisposing populations to meningo-
coccal outbreaks are poorly understood, the dry season with low
absolute humidity and dust linked to the Harmattan winds are
well known to be linked to this seasonal pattern [11]. Rising hu-
midity and the onset of the rains are established predictors of
the end of the epidemics [12].
Until 2010, NmAwas the main cause of meningitis epidemics
in Africa [6]. Since the introduction of mass population vacci-
nation with the group A meningococcal conjugate vaccine,
starting with Burkina Faso and parts of Mali and Niger at the
end of 2010, and continuing until 2016 [13], the proportion
of conﬁrmed meningitis cases due to this serogroup fell
Figure 3. Incidence rate of pathogens per 100 000 population among positive cerebrospinal samples before (2004–2010) (blue) and after (2011–2013)
(red) the introduction of vaccination with PsA-TT (MenAfriVac). Abbreviations: Hib, Haemophilus inﬂuenzae type b; Nm, Neisseria meningitidis; NmA,
Neisseria meningitidis group A; NmW, Neisseria meningitidis group W; Spn, Streptococcus pneumoniae.
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dramatically, as recorded in Burkina Faso and Chad [14–16].
The incidence of NmW rose in the meningitis season of 2010
before the introduction of PsA-TT and has remained at higher
levels since. An outbreak of NmX was seen in Niger in 2006
[17], and continues to cause a small proportion of cases,
while an outbreak of NmC was recorded in northern Nigeria
in 2013 and 2014 [18]. Other serogroups such as NmB and
NmY are rarely isolated in the meningitis belt. As the rollout
of PsA-TT campaigns was progressive between 2010 and
2013, the comparison before and after 2010 would beneﬁt
frommore reﬁned analyses; a mathematical model that takes ac-
count of the year of introduction of PsA-TT would help to more
accurately document the impact of PsA-TT on NmA and other
organisms. Although the rising proportion of laboratory conﬁr-
mation among suspected cases is encouraging, continued im-
provement in surveillance, including the development and
expansion of case-based surveillance [13], is needed to better de-
tect any changes in serogroup and pathogen distribution and
document the impact and long-term effectiveness of PsA-TT.
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